Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
A phase 2 trial of Rovalpituzumab tesirine in Small-cell lung cancer, run by AbbVie, completed.
Overview
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer is a phase 2 interventional study registered as NCT02674568 by AbbVie, with 342 participants recorded, started 2016-01-25 and reaching its primary completion in 2018-10-19. Interventions recorded: Rovalpituzumab tesirine. Conditions recorded: Small Cell Lung Cancer.
Linked to the drug Rovalpituzumab tesirine because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Small-cell lung cancer and the tag pipeline.
- TrialStudy Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
- TrialSNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Shares Small-cell lung cancer and the tag pipeline.